{"product_id":"veracyte-five-forces-analysis","title":"Veracyte Porter's Five Forces Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eA Must-Have Tool for Decision-Makers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eVeracyte faces moderate buyer power, specialized supplier leverage, significant regulatory and reimbursement barriers deterring new entrants, and escalating substitute diagnostics—while rivalry among genomics peers intensifies. This brief snapshot only scratches the surface. Unlock the full Porter's Five Forces Analysis to explore Veracyte’s competitive dynamics, market pressures, and strategic advantages in detail.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003euppliers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConcentrated sequencing platforms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVeracyte depends on a concentrated set of NGS platform providers—Illumina (~65% installed base in 2024) and Thermo Fisher (~25% in 2024)—creating supplier concentration risk. Platform lock-in and regulatory\/clinical validation requirements raise switching costs and extend revalidation timelines. Vendors can thus influence reagent pricing, service levels, and roadmap priorities. Designing multi-platform assays mitigates dependency but incurs materially higher development and validation costs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized reagents and consumables\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eProprietary kits, enzymes, and probes for Veracyte diagnostics are often single-sourced, creating concentrated supplier power. Batch consistency, quality and lead times directly affect test performance and turnaround time. Long-term supply agreements mitigate risk but commonly contain minimum purchase obligations and price escalators. Any supplier disruption can quickly curtail lab throughput and compress margins.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical samples and biobank access\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHigh-quality annotated specimens are essential for Veracyte’s test validation and iteration, yet access is concentrated in 3,000+ academic biobanks that wield bargaining leverage; data-use agreements and IRB constraints typically add 3–9 month delays to access and increase operational costs. Strategic collaborations and material-transfer agreements secure supply lines but often require revenue-sharing or milestone payments, compressing margins and tying sample availability to partner priorities.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCloud, bioinformatics, and data infrastructure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eComputational pipelines rely on dominant cloud vendors (AWS ~32%, Azure ~23%, Google Cloud ~11% in 2024) and licensed genomic databases; switching clouds is feasible but revalidation and security work add meaningful one-time and ongoing costs. Sudden storage\/compute price hikes can compress gross margins; preferred-pricing and multi-year contracts help dampen volatility. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDependence: high on top 3 clouds\u003c\/li\u003e\n\u003cli\u003eSwitch cost: revalidation\/security overhead\u003c\/li\u003e\n\u003cli\u003eRisk: price hikes → margin pressure\u003c\/li\u003e\n\u003cli\u003eMitigation: preferred pricing, multi-year deals\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIP licensing and patented biomarkers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIP licensing for signatures and patented biomarkers forces Veracyte to pay royalties and accept field-of-use limits, raising COGS and constraining clinical and geographic expansion; litigation over patents further strengthens supplier leverage. Building Veracyte-owned IP and filing defensive patents reduces dependency and lowers long-term margin pressure.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\u003c\/ul\u003e\n\u003cli\u003eRoyalties raise COGS and limit scale\u003c\/li\u003e\n\u003cli\u003eField-of-use clauses restrict market entry\u003c\/li\u003e\n\u003cli\u003eLitigation increases supplier bargaining power\u003c\/li\u003e\n\u003cli\u003eProprietary IP reduces reliance over time\u003c\/li\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePlatform concentration and cloud dependence raise revalidation costs and margin pressure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSupplier power is high: Illumina (~65% installed base in 2024) and Thermo Fisher (~25%) create platform concentration; proprietary reagents, IP royalties and 3,000+ biobanks (3–9 month access delays) further strengthen suppliers. Cloud dependence (AWS ~32%, Azure ~23%, Google ~11% in 2024) and single-source kits raise switching\/revalidation costs and margin risk.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eItem\u003c\/th\u003e\n\u003cth\u003e2024 Metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eIllumina share\u003c\/td\u003e\n\u003ctd\u003e~65%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eThermo Fisher share\u003c\/td\u003e\n\u003ctd\u003e~25%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAWS\u003c\/td\u003e\n\u003ctd\u003e~32%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAzure\u003c\/td\u003e\n\u003ctd\u003e~23%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGoogle Cloud\u003c\/td\u003e\n\u003ctd\u003e~11%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiobanks\u003c\/td\u003e\n\u003ctd\u003e3,000+ (3–9 mo delays)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImpact\u003c\/td\u003e\n\u003ctd\u003eHigher COGS, revalidation costs, margin pressure\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eTailored Porter's Five Forces analysis for Veracyte that uncovers key drivers of competition, buyer and supplier power, and market entry risks, identifying disruptive substitutes and emerging threats to market share. Detailed, strategic commentary highlights dynamics that deter new entrants, influence pricing and profitability, and support investor or internal strategy use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eClear one-sheet Porter's Five Forces for Veracyte—reduces analysis time and highlights competitive pressures at a glance, customizable with new data and ready to drop into pitch decks or executive reports.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePayers drive reimbursement and coverage\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePrivate insurers and CMS set coverage and rates, controlling reimbursement for over 50% of US health spend (~$4.5T in 2023), concentrating buyer power. Strict evidence thresholds and utilization management make demand highly elastic for Veracyte tests. Repricing cycles and prior authorization commonly delay collections by 4–12 weeks. Strong health-economic data and guideline inclusion can secure high-single to low-double-digit uplift in negotiated reimbursement.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealth systems and IDNs consolidate volume\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLarge health systems, GPOs and reference labs now aggregate most testing volume and can demand discounts, EMR integration and strict SLAs; Veracyte reported full‑year 2024 revenue of $373.8 million, so major contract wins or losses materially shift share and quarterly results. Embedded workflows and EMR integration raise switching costs for buyers, favoring Veracyte when contracts lock in referrals and operational pathways.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialist physicians as gatekeepers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePulmonologists, endocrinologists and pathologists act as gatekeepers for Veracyte tests, prioritizing turnaround time, ease of use and demonstrated clinical validity when deciding adoption. In 2024 KOL endorsements and peer‑reviewed outcomes continued to lower perceived risk and accelerate referrals. When comparable in‑house alternatives exist, clinicians exhibit higher price sensitivity, reducing Veracyte's negotiating leverage.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatients and advocacy groups\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003ePatients have limited direct bargaining power but can sway payer policy through organized advocacy; groups focused on lung disease and ILD have helped accelerate coverage for diagnostic genomic tools. Out-of-pocket exposure suppresses uptake in marginal cases, while transparent reports and patient support programs lower financial and administrative friction.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePatients influence payer decisions via advocacy\u003c\/li\u003e\n\u003cli\u003eAdvocacy speeds coverage in lung\/ILD\u003c\/li\u003e\n\u003cli\u003eOut-of-pocket costs reduce demand\u003c\/li\u003e\n\u003cli\u003eTransparent reports\/support cut uptake friction\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInternational distributors and partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eOutside the U.S., international distributors and partners control market access and negotiate margins, exclusivity, and regulatory support, giving buyers strong bargaining power; currency fluctuations and public tender dynamics further amplify leverage, while co-development and localization strategies can rebalance negotiating strength in Veracyte’s favor.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePartner control: market access\u003c\/li\u003e\n\u003cli\u003eNegotiation: margins, exclusivity, regulatory support\u003c\/li\u003e\n\u003cli\u003eExternal factors: currency, tenders\u003c\/li\u003e\n\u003cli\u003eMitigants: co-development, localization\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePayer concentration controls reimbursement, causing \u003cstrong\u003e4–12\u003c\/strong\u003e week collection delays\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePayers (private+CMS) concentrate power, controlling reimbursement amid \u0026gt;50% of US health spend (~$4.5T in 2023), making demand elastic for Veracyte. Repricing\/prior auth commonly delay collections 4–12 weeks; strong HEOR\/guideline inclusion can lift negotiated rates high-single to low-double digits. Large systems\/GPOs and labs demand discounts; Veracyte full‑year 2024 revenue was $373.8M. Patients influence payers via advocacy but limited direct bargaining power.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eUS health spend (2023)\u003c\/td\u003e\n\u003ctd\u003e$4.5T\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVeracyte FY2024 revenue\u003c\/td\u003e\n\u003ctd\u003e$373.8M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eReimbursement delay\u003c\/td\u003e\n\u003ctd\u003e4–12 weeks\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview the Actual Deliverable\u003c\/span\u003e\u003cbr\u003eVeracyte Porter's Five Forces Analysis\u003c\/h2\u003e\n\u003cp\u003eThis preview shows the exact Veracyte Porter's Five Forces Analysis you'll receive immediately after purchase—no placeholders or sample text. It is the full, professionally formatted document ready for download and use the moment you buy. You're viewing the final deliverable, identical to the file provided post-payment. No surprises, just immediate access to the complete analysis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"PortersFiveForce","offers":[{"title":"Default Title","offer_id":56162983641465,"sku":"veracyte-five-forces-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0914\/5276\/8633\/files\/veracyte-five-forces-analysis.png?v=1762712567","url":"https:\/\/portersfiveforce.com\/products\/veracyte-five-forces-analysis","provider":"Porter's Five Forces","version":"1.0","type":"link"}